Literature DB >> 33741715

EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.

Jennifer A Jiménez1, April A Apfelbaum1,2,3, Allegra G Hawkins4,5, Laurie K Svoboda6, Abhijay Kumar1, Ramon Ocadiz Ruiz1, Alessandra X Garcia1, Elena Haarer1, Zeribe C Nwosu7, Joshua Bradin1, Trupta Purohit8, Dong Chen8, Tomasz Cierpicki8, Jolanta Grembecka8, Costas A Lyssiotis7,9, Elizabeth R Lawlor10,2,3,8.   

Abstract

Ewing sarcomas are driven by EWS-ETS fusions, most commonly EWS-FLI1, which promotes widespread metabolic reprogramming, including activation of serine biosynthesis. We previously reported that serine biosynthesis is also activated in Ewing sarcoma by the scaffolding protein menin through as yet undefined mechanisms. Here, we investigated whether EWS-FLI1 and/or menin orchestrate serine biosynthesis via modulation of ATF4, a stress-response gene that acts as a master transcriptional regulator of serine biosynthesis in other tumors. Our results show that in Ewing sarcoma, ATF4 levels are high and that ATF4 modulates transcription of core serine synthesis pathway (SSP) genes. Inhibition of either EWS-FLI1 or menin leads to loss of ATF4, and this is associated with diminished expression of SSP transcripts and proteins. We identified and validated an EWS-FLI1 binding site at the ATF4 promoter, indicating that the fusion can directly activate ATF4 transcription. In contrast, our results suggest that menin-dependent regulation of ATF4 is mediated by transcriptional and post-transcriptional mechanisms. Importantly, our data also reveal that the downregulation of SSP genes that occurs in the context of EWS-FLI1 or menin loss is indicative of broader inhibition of ATF4-dependent transcription. Moreover, we find that menin inhibition similarly leads to loss of ATF4 and the ATF4-dependent transcriptional signature in MLL-rearranged B-cell acute lymphoblastic leukemia, extending our findings to another cancer in which menin serves an oncogenic role. IMPLICATIONS: These studies provide new insights into metabolic reprogramming in Ewing sarcoma and also uncover a previously undescribed role for menin in the regulation of ATF4. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33741715      PMCID: PMC8462528          DOI: 10.1158/1541-7786.MCR-20-0679

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  49 in total

1.  Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.

Authors:  Jason W Locasale; Alexandra R Grassian; Tamar Melman; Costas A Lyssiotis; Katherine R Mattaini; Adam J Bass; Gregory Heffron; Christian M Metallo; Taru Muranen; Hadar Sharfi; Atsuo T Sasaki; Dimitrios Anastasiou; Edouard Mullarky; Natalie I Vokes; Mika Sasaki; Rameen Beroukhim; Gregory Stephanopoulos; Azra H Ligon; Matthew Meyerson; Andrea L Richardson; Lynda Chin; Gerhard Wagner; John M Asara; Joan S Brugge; Lewis C Cantley; Matthew G Vander Heiden
Journal:  Nat Genet       Date:  2011-07-31       Impact factor: 38.330

2.  Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study.

Authors:  Gregory T Armstrong; Toana Kawashima; Wendy Leisenring; Kayla Stratton; Marilyn Stovall; Melissa M Hudson; Charles A Sklar; Leslie L Robison; Kevin C Oeffinger
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

3.  Menin‑MLL inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells.

Authors:  Ichiroh Kato; Takashi Kasukabe; Shunichi Kumakura
Journal:  Int J Oncol       Date:  2020-08-28       Impact factor: 5.650

4.  Both transcriptional regulation and translational control of ATF4 are central to the integrated stress response.

Authors:  Souvik Dey; Thomas D Baird; Donghui Zhou; Lakshmi Reddy Palam; Dan F Spandau; Ronald C Wek
Journal:  J Biol Chem       Date:  2010-08-23       Impact factor: 5.157

Review 5.  Menin: a scaffold protein that controls gene expression and cell signaling.

Authors:  Smita Matkar; Austin Thiel; Xianxin Hua
Journal:  Trends Biochem Sci       Date:  2013-07-10       Impact factor: 13.807

6.  Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.

Authors:  Saravana P Selvanathan; Garrett T Graham; Hayriye V Erkizan; Uta Dirksen; Thanemozhi G Natarajan; Aleksandra Dakic; Songtao Yu; Xuefeng Liu; Michelle T Paulsen; Mats E Ljungman; Cathy H Wu; Elizabeth R Lawlor; Aykut Üren; Jeffrey A Toretsky
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-03       Impact factor: 11.205

Review 7.  Surviving Stress: Modulation of ATF4-Mediated Stress Responses in Normal and Malignant Cells.

Authors:  Inge M N Wortel; Laurens T van der Meer; Michael S Kilberg; Frank N van Leeuwen
Journal:  Trends Endocrinol Metab       Date:  2017-08-07       Impact factor: 12.015

8.  EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.

Authors:  Sameer H Issaq; Arnulfo Mendoza; Ria Kidner; Tracy I Rosales; Damien Y Duveau; Christine M Heske; Jason M Rohde; Matthew B Boxer; Craig J Thomas; Ralph J DeBerardinis; Lee J Helman
Journal:  Mol Cancer Ther       Date:  2020-05-05       Impact factor: 6.261

9.  The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.

Authors:  Andrew S Brohl; David A Solomon; Wendy Chang; Jianjun Wang; Young Song; Sivasish Sindiri; Rajesh Patidar; Laura Hurd; Li Chen; Jack F Shern; Hongling Liao; Xinyu Wen; Julia Gerard; Jung-Sik Kim; Jose Antonio Lopez Guerrero; Isidro Machado; Daniel H Wai; Piero Picci; Timothy Triche; Andrew E Horvai; Markku Miettinen; Jun S Wei; Daniel Catchpool; Antonio Llombart-Bosch; Todd Waldman; Javed Khan
Journal:  PLoS Genet       Date:  2014-07-10       Impact factor: 5.917

10.  Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium.

Authors:  Raushan T Kurmasheva; Abhik Bandyopadhyay; Edward Favours; Vanessa Del Pozo; Samson Ghilu; Doris A Phelps; Gerard M McGeehan; Stephen W Erickson; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2020-04-25       Impact factor: 3.167

View more
  1 in total

1.  One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma.

Authors:  Guillermo Flores; Patrick J Grohar
Journal:  J Bone Oncol       Date:  2021-12-01       Impact factor: 4.072

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.